| Under the background of rapid economic development and industrial transformation and upgrading,contemporary industries are gradually developing into the form of industrial clusters.At the same time,China’s"14th Five-Year Plan" has been further defined.Accelerating the cultivation to expand strategic emerging industries and the formation of more new economic growth points is the only way to build high-quality industries.Among them,the biological industry,as a strategic emerging industry,is not only crucial to the development of a country,but also closely related to the happiness index of the people.Therefore,in recent years,the biological industry has gradually increased the attention of the country and the capital market,and the biological industry cluster enterprises have accelerated the improvement of the income and scale of the whole biological industry cluster through a series of value creation behaviors.At the same time,under the trend of multi-polar changes in the global economic pattern,the biological industry cluster has also ushered in brand-new opportunities and challenges.Among them,Harbin Pharmaceutical,the leading enterprise in the biological industry cluster,fully defines the value creation path of the enterprise,improves the performance of the enterprise and the status of the enterprise in the industrial cluster through effective allocation and utilization of resources,orderly production and operation,and comprehensive implementation of strategic measures.In addition,it actively speaks out in the biological industry cluster,which promotes the improvement of the overall performance of the industrial cluster through the value creation of enterprises,and promotes the sustainable development of the biological industry cluster in the future.As more important in the biological industry cluster biological medicine industry cluster leading enterprises,Harbin medicine shares has certain influence on the development of industrial cluster,so this paper selects Harbin medicine shares as a case enterprise,combined with the operation of the enterprise from 2014 to 2021,the integrated use of literature analysis,case study and comparative analysis of three methods,research and analysis of biological industry cluster enterprise value creation on enterprise performance.Due to the biological industry enterprises have the characteristics of high capital and technology intensive.investment returns and future instability,to ensure the data analysis reliability and rigor,this paper choose from the horizontal and vertical two dimensions comparison analysis the influence of the value of creation of cluster enterprise performance,horizontal dimension selected 20 listed biological industry cluster enterprises in 2021 by the DEA analysis method,the longitudinal dimension selected Harbin medicine shares from 2014 to 2021 related data compared by the DEA analysis.At the same time,considering the characteristics of cluster enterprises compared with ordinary enterprises,we choose to combine qualitative and quantitative analysis of value creation and enterprise performance from the perspectives of their own development and industrial development.The BCC model in DEA analysis is used to obtain efficiency,and make systematic analysis combined with the production and operation conditions.Through the analysis of the relevant enlightenment of the relationship between value creation and enterprise performance,we put forward reasonable suggestions on the value creation path of Harbin Pharmaceutical Shares,hoping to provide reference for the biological industry cluster enterprises to improve enterprise performance in the stage of modernization transformation. |
PDF Full Text Request